EC Psychology And Psychiatry

Research Article Volume 12 Issue 11 - 2023

RNA m6A Methylation in Psychiatric Disorders

Qiao Mao1#, Jessica Luo2#, Xinqun Luo3, Xiaoyu Zhu4, Kesheng Wang5, Lingjun Zuo6, Yong Zhang7 and Xingguang Luo4*

1Department of Psychosomatic Medicine, People’s Hospital of Deyang City, Deyang, Sichuan, China
2Northeastern University Khoury College of Computer Sciences, Boston, MA, USA
3Department of Neurosurgery, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, China
4Beijing Huilongguan Hospital, Peking University Huilongguan Clinical School of Medicine, Beijing, China
5Department of Family and Community Health, School of Nursing, Health Sciences Center, West Virginia University, Morgantown, WV, USA
6Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
7Tianjin Mental Health Center, Tianjin, China
*Corresponding Author: Xingguang Luo, Beijing Huilongguan Hospital, Peking University Huilongguan Clinical School of Medicine, Beijing, China.
Received: November 18, 2023; Published: December 05, 2023



This comprehensive review introduces the features of m6A modification and its role in neuropsychiatric disorders. The research findings suggest that m6A modifications and their regulators play a critical role in the occurrence and development of major psychiatric disorders, especially Alzheimer’s disease, affecting synaptic protein synthesis, subtype classification, immune infiltration, pathogenesis, and inflammatory infiltration. These findings highlight m6A regulators as potential new diagnostic and therapeutic targets, with m6A methyltransferase METTL3 being the best-characterized regulator in these diseases. The review concludes that m6A modification is a promising target for the prevention and treatment of major psychiatric disorders.

 Keywords: m6A Modification; Neuropsychiatric Disorders; Alzheimer’s Disease; m6A Regulator; METTL3

  1. Mathoux J., et al. “Regulatory mechanisms of the RNA modification m(6)A and significance in brain function in health and disease”. Frontiers in Cellular Neuroscience 15 (2021): 671932.
  2. Mitsuhashi H and Nagy C. “Potential roles of m6A and FTO in synaptic connectivity and major depressive disorder”. International Journal of Molecular Sciences7 (2023): 6220.
  3. Du T., et al. “An association study of the m6A genes with major depressive disorder in Chinese Han population”. Journal of Affective Disorders 183 (2015): 279-286.
  4. Edupuganti RR., et al. “N(6)-methyladenosine (m(6)A) recruits and repels proteins to regulate mRNA homeostasis”. Nature Structural and Molecular Biology 10 (2017): 870-878.
  5. Jan SM., et al. “Integrative genomic analysis of m6a-SNPs identifies potential functional variants associated with alzheimer's disease”. ACS Omega14 (2023): 13332-13341.
  6. Zhang Y., et al. “Roles of m6A modification in neurological diseases”. Zhong Nan Da Xue Xue Bao Yi Xue Ban1 (2022): 109-115.
  7. Lan Y., et al. “The role of M(6)A modification in the regulation of tumor-related lncRNAs”. Molecular Therapy - Nucleic Acids 24 (2021): 768-779.
  8. Huang H., et al. “Altered expression of the m6A methyltransferase METTL3 in Alzheimer's disease”. eNeuro 5 (2020).
  9. Castro-Hernandez R., et al. “Conserved reduction of m(6)A RNA modifications during aging and neurodegeneration is linked to changes in synaptic transcripts”. Proceedings of the National Academy of Sciences of the United States of America9 (2023): e2204933120.
  10. Zhang X., et al. “Differential methylation of circRNA m6A in an APP/PS1 Alzheimer's disease mouse model”. Molecular Medicine Reports 2 (2023): 55.
  11. Wang Y., et al. “m6A regulator-mediated RNA methylation modification patterns are involved in the pathogenesis and immune microenvironment of depression”. Frontiers in Genetics 13 (2022): 865695.
  12. Ming Y., et al. “m6A methyltransferase METTL3 reduces hippocampal neuron apoptosis in a mouse model of autism through the MALAT1/SFRP2/Wnt/beta-catenin axis”. Psychiatry Investigation 10 (2022): 771-787.
  13. Liu Y and Zhang H. “RNA m6A modification changes in postmortem nucleus accumbens of subjects with alcohol use disorder: a pilot study”. Genes 6 (2022): 958.
  14. Li M., et al. “Novel roles of RNA m6A methylation regulators in the occurrence of alzheimer's disease and the subtype classification”. International Journal of Molecular Sciences18 (2022): 10766.
  15. Zhao F., et al. “METTL3-dependent RNA m(6)A dysregulation contributes to neurodegeneration in Alzheimer's disease through aberrant cell cycle events”. Molecular Neurodegeneration 1 (2021): 70.
  16. Tang Z., et al. “KDM1A-mediated upregulation of METTL3 ameliorates alzheimer's disease via enhancing autophagic clearance of p-Tau through m6A-dependent regulation of STUB1”. Free Radical Biology and Medicine 195 (2023): 343-358.
  17. Du B., et al. “N6-methyladenosine (m6A) modification and its clinical relevance in cognitive dysfunctions”. Aging (Albany NY)16 (2021): 20716-20737.
  18. Deng Y., et al. “Identification of the function and mechanism of m6A reader IGF2BP2 in Alzheimer's disease”. Aging (Albany NY)21 (2021): 24086-24100.
  19. Han M., et al. “Abnormality of m6A mRNA methylation is involved in alzheimer's disease”. Frontiers in Neuroscience 14 (2020): 98.
  20. Yang Y., et al. “Constant light exposure in early life induces m6A-mediated inhibition of IGF gene family in the chicken”. Journal of Animal Science 7 (2022): skac199.
  21. Niu J., et al. “Mechanism of METTL3-mediated m6A modification in depression-induced cognitive deficits”. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 3-4 (2022): 86-99.
  22. Bai L., et al. “m6A Demethylase FTO regulates dopaminergic neurotransmission deficits caused by arsenite”. Toxicological Sciences 2 (2018): 431-446.
  23. Xiong X., et al. “Genetic drivers of m(6)A methylation in human brain, lung, heart and muscle”. Nature Genetics 8 (2021): 1156-1165.
  24. Yoon KJ., et al. “Temporal control of mammalian cortical neurogenesis by m(6)A methylation”. Cell4 (2017): 877-889 e817.

Xingguang Luo., et al. “RNA m6A Methylation in Psychiatric Disorders” ”. EC Psychology and Psychiatry  12.11 (2023): 01-06.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net